Biochemical toxicology of chemical teratogenesis

Critical Reviews in Biochemistry and Molecular Biology

Volumn 31, Issue 1, 1996, Pages 1-40

  Wells, Peter G ^a,b   Winn, Louise M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

benzo a pyrene; chemical developmental toxicology; cytochromes P450; cytoprotection; electrophiles teratogenesis; elimination; free radicals; molecular targets; oxidative stress; phenytoin; prostaglandin H synthase; reactive intermediates; reactive oxygen species; repair; thalidomide

Indexed keywords

2 NAPHTHYLAMINE; AZO COMPOUND; BENZO[A]PYRENE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DIETHYLSTILBESTROL; DIMETHADIONE; FREE RADICAL; GLUTATHIONE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; HYDROXYL RADICAL; ISOTRETINOIN; LIPOXYGENASE; N (2 FLUORENYL)ACETAMIDE; NITRO DERIVATIVE; PARACETAMOL; PEROXIDASE; PHENYTOIN DERIVATIVE; PROSTAGLANDIN SYNTHASE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TERATOGENIC AGENT; THALIDOMIDE; TRIMETHADIONE; XENOBIOTIC AGENT;

BIOCHEMISTRY; CELL PROTECTION; CHEMICAL TERATOGENESIS; DETOXIFICATION; EMBRYOTOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TOXICOLOGY; XENOBIOTIC METABOLISM;

EID: 0029968112     PISSN: 10409238     EISSN: None     Source Type: Journal    
DOI: 10.3109/10409239609110574     Document Type: Review

References (204)

1. Anderson, M. E., Powrie, F., Puri, R. N., and Meister, A. 1985. Glutathione monoethyl ester: preparation, uptake by tissues, and conversion to glutathione. Arch. Biochem. Biophys. 239: 538-548.
2. Anderson, M. E. and Meister. A. 1989. Glutathione monoesters. Anal. Biochem. 183: 16-20.
3. Arlen, R. R. and Wells, P. G. 1989. Effect of the cyclooxygenase inhibitor acetylsalicylic acid on thalidomide teratogenicity in New Zealand white rabbits. FASEB J. 3: A1025.
4. Arlen, R. R. and Wells, P. G. 1996. Inhibition of thalidomide teratogenicity by acetylsalicylic acid: evidence for prostaglandin H synthetase-catalysed bioactivation of thalidomide to a teratogenic reactive intermediate in the New Zealand white rabbit. J. Pharmacol. Exp. Ther. In press.
5. Arlen, R. R. and Wells, P. G. 1990. Extracellular thiol-disulfide status reflecting chemical toxicity mediated via oxidative stress: validation with paraquat and t-butylhydroperoxide, and implications for phenytoin and thalidomide teratogenicity. FASEB J. 4: A608.
6. Arlen, R. A. and Wells, P. G. Submitted. Extracellular thiol-disulfide status reflecting chemical toxicity mediated via oxidative stress: validation with paraquat and t-butylhydroperoxide, and implications for phenytoin and thalidomide teratogenicity.
7. Ashby, R., Davis, L., Dewhurst, B. B., Espinal, R., Penn, R. N., and Upshall, D. G. 1976. Aspects of the teratology of cyclophosphamide (NSC-26271). Cancer Treat. Rep. 60: 477-482.
8. Balling, R., Haaf, M., Maydl, R., Metzler, M., and Beier, H. M. 1985. Oxidative and conjugative metabolism of diethylstilbestrol by rabbit preimplantation embryos. Dev. Biol. 109: 370-378.
9. Benson, A. J., Martin, C. N., and Garner, R. C. 1988. N-(2-Hydroxyethyl)-N-[2-(7-guaninyl) ethyl], the putative major DNA adduct of cyclophosphamide in vitro and in vivo in the rat. Biochem. Pharmacol. 37: 2979-2985.
10. Bochert, G., Platzek, R., Rahm, U., and Webb, J. 1978. Some new aspects in the study of DNA alkylation in embryonic and fetal tissues. In: Role of Pharmacokinetics in Prenatal and Perinatal Toxicology, pp. 253-261. (Neubert, D., Merker, H.-J., Nau, H., and Langman, J., Eds.) Stuttgart: Georg Thieme Verlag.
11. Boyd, J. A., Harvan, D. J., and Eling, T. E. 1983. The oxidation of 2-aminofluorene by prostaglandin endoperoxide synthetase. J. Biol. Chem. 258: 8246-8254.
12. Boyd, J. A. and Eling, T. E. 1987. Prostaglandin H synthase-catalyzed metabolism and DNA binding of 2-naphthylamine. Cancer Res. 47: 4007-4014.
13. Boyd, J. A. and Eling, T. E. 1984. Evidence for a one-electron mechanism of 2-aminofluorene oxidation by prostaglandin H synthase and horseradish peroxidase. J. Biol. Chem. 259: 13885-13896.
14. Braun, A. G., Harding, F. A., and Weinreb, S. L. 1986. Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicol. Appl. Pharmacol. 82: 175-179.
15. Brierly, C. H. and Burchell, B. 1993. Human UDP-glucuronosyl transferases: chemical defence, jaundice and gene therapy. Bioessays 15: 749-754.
16. Buehler, B. A. 1984. Epoxide hydrolase activity and fetal hydantoin syndrome. Proc. Greenwood Genet. Cent. 3: 109-110.
17. Buehler, B. A., Delimont, D., VanWaes, M., and Finnell, R. H. 1990. Prenatal prediction of risk of the fetal hydantoin syndrome. N. Engl. J. Med. 322: 1567-1572.
18. Burchell, B. 1973. Observations of uridine diphosphate glucuronyltransferase activity towards oestriol and xenobiotics in developing and cultured tissues from mouse and man. Biochem. Soc. Trans. 1: 1212-1214.
19. Burchell, B. and Dutton, G. J. 1975. Delayed induction by phenobarbital of UDP-glucuronyltransferase activity towards bilirubin in fetal liver. Biol. Neonate 26: 122-128.
20. Burchell, B. and Coughtrie, M. W. H. 1989. UDP-glucuronosyltransferase. Pharmacol. Ther. 43: 261-289.
21. Burchell, B., Coughtrie, M. W. H., and Jansen, P. L. M. 1994. Function and regulation of UDP-glucuronosyltransferase genes in health and liver disease: report of the seventh international workshop on glucuronidation, September 1993, Pitlochry, Scotland. Hepatology 20: 1622-1630.
22. Byczkowski, J. Z. and Kulkarni, A. P. 1989. Lipoxygenase-catalyzed epoxidation of benzo[a]pyrene-7,8-dihydrodiol. Biochem. Biophys. Res. Commun. 159: 1199-1205.
23. Carpenter, S. P. and Raucy, J. L. 1995. CYP2E1: a putative role in chemical-mediated teratogenesis. Proc. Int. Soc. Study Xenobiot. 8: 238.
24. Chung, C. S. and Myrianthopoulos, N. C. 1975. Factors affecting risks of congenital malformations. In: The National Foundation March of Dimes, Original Articles Series, Vol. 11.
25. Chung, A.-S., Maines, M. D., and Reynolds, W. A. 1982. Inhibition of the enzymes of glutathione metabolism by mercuric chloride in the rat kidney: reversal by selenium. Biochem. Pharmacol. 31: 3093-3100.
26. 1 by lipoxygenase purified from human term placenta and intrauterine conceptal tissues. Teratology 50: 311-317.
27. Degen, G. H., Eling, T. E., and McLachlan, J. A. 1982. Oxidative metabolism of diethylstilbestrol by prostaglandin synthetase. Cancer Res. 42: 919-923.
28. DeSesso, J. M. 1979. Cell death and free radicals: a mechanism for hydroxyurea teratogenesis. Med. Hypoth. 5: 937-951.
29. DeSesso, J. M., Scialli, A. R., and Goeringer, G. C. 1994. D-Mannitol, a specific hydroxyl free radical scavenger, reduces the developmental toxicity of hydroxyurea in rabbits. Teratology 49: 248-259.
30. DeSesso, J. M. and Goeringer, G. C. 1990. Ethoxyquin and nordihydroguaiaretic acid reduce hydroxyurea developmental toxicity. Reprod. Toxicol. 4: 267-275.
31. Dierickx, P. J. 1982. In vitro inhibition of the soluble glutathione S-transferases from rat liver by heavy metals. Enzyme 27: 25-32.
32. 32P nuclear magnetic resonance spectroscopy. Chem. Biol. Interact. 93: 185-196.
33. Doecke, C. J., Veronese, M. E., Pond, S. M., Miners, J. O., Birkett, D. J., Sansom, L. N., and McManus, M. E. 1991. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br. J. Clin. Pharmacol. 1: 125-130.
34. Dutton, G. J. 1971. Glucuronide-forming enzymes. In: Handbook of Experimental Pharmacology, Vol. 28:2, pp. 378-400. (Brodie and Gillette, Eds.) Berlin: Springer-Verlag.
35. Edmonds, L., Hatch, M., Holmes, L., Kline, J., Letz, G., Levin, B., Miller, R., Shrout, P., Stein, Z., Warburton, D., Weinstock, M., Whorton, R. D., and Wyrobek, A. 1981. Report of panel II: guidelines for reproductive studies in exposed human populations. In: Guidelines for Studies of Human Populations Exposed to Mutagenic and Reproductive Hazards. (Bloom, A. D., Ed.) White Plains, NY: March of Dimes Birth Defects Foundation.
36. Eriksson, U. J. and Borg, L. A. H. 1991. Protection by free oxygen radical scavenging enzymes against glucose-induced embryonic malformations in vitro. Diabetologia 34: 325-331.
37. Eriksson, U. J. and Borg, L. A. H. 1993. Diabetes and embryonic malformations: role of substrata-induced free-oxygen radical production for dysmorphogenesis in cultured rat embryos. Diabetes 42: 411-419.
38. Fantel, A. G., Greenaway, J. C., Juchau, M. R., and Shepard, T. H. 1979. Teratogenic bioactivation of cyclophosphamide in vitro. Life Sci. 25: 67-72.
39. Fantel, A. G. 1982. Culture of whole rodent embryos in teratogen screening. Teratogen. Carcinogen. Mutagen. 2: 231-234.
40. Fantel, A. G., Pereson, R. E., Tracy, J. W., and Juchau, M. R. 1988. Niridazole metabolism by rat embryos in vitro. Teratology 37: 213-221.
41. Fantel, A. G., Barber, C. V., Carda, M. B., Tumbic, R. W., and Mackler, B. 1992. Studies of the role of ischemia/reperfusion and superoxide anion radical production in the teratogenicity of cocaine. Teratology 46: 293-300.
42. Faustman-Watts, E. M., Greenaway, J. C., Namkung, M. J., Fantel, A. G., and Juchau, M. R. 1983. Teratogenicity in vitro of 2-acetylaminofluorene: role of biotransformation. Teratology 27: 19-28.
43. Faustman-Watts, E. M., Giachelli, C. M., and Juchau, M. R. 1986. Carbon monoxide inhibits monooxygenation by the conceptus and embryotoxic effects of proteratogens in vitro. Toxicol. Appl. Pharmacol. 83: 590-595.
44. Filler, R. and Lew, K. J. 1981. Developmental onset of mixed-function oxidase activity in preimplantation mouse embryos. Proc. Natl. Acad. Sci. U.S.A., 78: 6991-6995.
45. Finnell, R. H. and Chernoff, C. F. 1987. Geneteratogen interactions: an approach to understanding the metabolic basis of birth defects. In: Pharmacokinetics in Teratogenesis, Vol. 2. pp. 97-109. (Nau, H. and Scott, W., Eds.) New York: CRC Press.
46. Finnell, R. H., Kerr, B. M., van Waes, M., Steward, R. L., and Levy, R. H. 1994. Protection from phenytoin-induced congenital malformations by coadministration of the antiepileptic drug stiripentol in a mouse model. Epilepsia 35: 141-148.
47. Fort, D. J., Stover, E. L., Rayburn, J. R., Huli, M., and Bantle, J. A. 1993. Evaluation of the developmental toxicity of trichloroethylene and detoxification metabolites using Xenopus. Teratogen. Carcinogen. Mutagen. 13: 35-45.
48. Frank, A. A., Collier, J. M., Forsyth, C. S., Zeng, W., and Stoner, G. D. 1993. Ellagic acid embryoprotection in vitro: distribution and effects on DNA adduct formation. Teratology 47: 275-280.
49. Frischer, H., Bowman, J. E., Carson, P. E., Rieckmann, K. H., Willerson, D., and Colwell, E. J. 1973. Erythrocyte glutathione reductase, glucose-6-phosphate dehydrogenase and 6-phosphogluconic dehydrogenase deficiencies in populations of the United States. South Vietnam, Iran and Ethiopia. J. Lab. Clin. Med. 81: 603.
50. Gibson, J. E. and Becker, B. A. 1968. Effect of phenobarbital and SKF 525-A on the teratogenicity of cyclophosphamide in mice. Teratology 1: 393-398.
51. Gonzalez, F. J. 1995. Genetic polymorphism and cancer susceptibility. Fourteenth Sapporo Cancer Seminar. Cancer Res. 55: 710-715.
52. Gordon, G. B., Spielberg, S. P., Blake, D. A., and Balasubramanian, V. 1981. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci. U.S.A. 78: 2545-2548.
53. Gordon, G. B., Spielberg, S. P., Blake, D. A., and Balasubramanian, V. 1983. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci. U.S.A. 78: 2545-2548.
54. Goto, Y., Noda, Y., Mori, T., and Nakano, M. 1993. Increased generation of reactive oxygen species in embryos cultured in vitro. Free Rad. Biol. Med. 15: 69-75.
55. Greenaway, J. C. and Fantel, A. G. 1983. Enhancement of rifampin teratogenicity in cultured rat embryos. Toxicol. Appl. Pharmacol. 69: 81-88.
56. Guengerich, F. P. and Shimada, T. 1991. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4: 391-407.
57. Hales, B. F. 1981a. Modification of the mutagenicity and teratogenicity of cyclophosphamide in rats with inducers of the cytochromes P-450. Teratology 24: 1-11.
58. Hales, B. F. 1981b. Modification of the teratogenicity and mutagenicity of cyclophosphamide with thiol compounds. Teratology 23: 373-381.
59. Halliwell, B. and Gutteridge, J. M. C. 1989. Protection against oxidants in biological systems: the superoxide theory of oxygen toxicity. In: Free Radicals in Biology and Medicine, pp. 86-187. (Halliwell, B. and Gutteridge, J. M. C., Eds.) London: Oxford University Press.
60. Halliwell, B., Kaur, H., and Ingelman-Sundberg, M. 1991. Hydroxylation of salicylate as an assay for hydroxyl radicals: a cautionary note. Free Rad. Biol. Med. 10: 439-441.
61. Hansen, D. K. 1991. The embryotoxicity of phenytoin: an update on possible mechanisms. Proc. Soc. Exp. Biol. Med. 197: 361-368.
62. Harbison, R. D. 1978. Chemical-biological reactions common to teratogenesis and mutagenesis. Environ. Health Perspect. 24: 87-100.
63. Harbison, R. D. and Becker, B. A. 1971. Effects of phenobarbital or SKF525A pretreatment on diphenylhydantoin disposition in pregnant mice. Toxicol. Appl. Pharmacol. 20: 573-581.
64. Harbison, R. D. and Becker, B. A. 1974. Comparative embryotoxicity of diphenylhydantoin and some of its metabolites in mice. Teratology 10: 237-242.
65. Harris, C., Stark, K. L., and Juchau, M. R. 1988. Glutathione status and the incidence of neural tube defects elicited by direct acting teratogens in vitro. Teratology 37: 577-590.
66. Harris, C., Stark, K. L., Luchtel, D. L., and Juchau, M. R. 1989. Abnormal neurulation induced by 7-hydroxy-2-acetylaminofluorene and acetaminophen: evidence for catechol metabolites as proximate dysmorphogens. Toxicol. Appl. Pharmacol. 101: 432-447.
67. Heinonen, O. P., Slone, D., and Shapiro, S. 1977. Birth Defects and Drugs in Pregnancy, pp. 127, 450. Littleton, MA: PSG.
68. High, K. A. and Kubow, S. 1994. n-3 fatty acids inhibit defects and fatty acid changes caused by phenytoin in early gestation in mice. Lipids 29: 771-778.
69. Hiranruengchok, R. and Harris, C. 1993. Glutathione oxidation and embryotoxicity elicited by diamide in the developing rat conceptus in vitro. Toxicol. Appl. Pharmacol. 120: 62-71.
70. 1-DNA adducts in human placenta and cord blood. Cancer Res. 53: 1278-1280.
71. Hume, R. 1993. Proc. 7th Annual Workshop on Glucuronidation and the UDP-Glucuronosyltransferases, p. 7. Pitlochry, Scotland.
72. Iyer, P., Martin, J. E., and Irvin, T. R. 1991. Role of biotransformation in the in vitro preimplantation embryotoxicity of naphthalene. Toxicology 66: 257-270.
73. Jellum, E., Marstein, S., Skullerud, K., and Munthe, E. 1983. Glutathione in pyroglutamic aciduria (5-oxoprolinuria) and rheumatoid arthritis. In: Functions of Glutathione: Biochemical, Physiological, Toxicological and Clinical Aspects, pp. 325-336. (Larsson, A., Orrenius, S., Holmgren, A., and Mannervik, B., Eds.) New York: Raven Press.
74. Jones, A. L., Hume, R., Bamford, K. J., and Coughtrie, W. H. 1992. Estrogen and phenol sulfotransferase activities in human fetal lung. Early Hum. Dev. 28: 65-77.
75. Juchau, M. R. 1981. Enzymatic bioactivation and inactivation of chemical teratogens and transplacental carcinogens/mutagens. In: The Biochemical Basis of Chemical Teratogenesis, pp. 63-94. New York: Elsevier.
76. Juchau, M. R., Bark, D. H., Shewey, L. M., and Greenaway, J. C. 1985a. Generation of reactive dysmorphogenic intermediates by rat embryos in culture: effects of cytochrome P-450 inducers. Toxicol. Appl. Pharmacol. 81: 533-544.
77. Juchau, M. R., Giachelli, C. M., Fantel, A. G., Greenaway, J. C., Shepard, T. H., and Faustman-Watts, E. M. 1985b. Effects of 3-methylcholanthrene and phenobarbital on the capacity of embryos to bioactivate teratogens during organogenesis. Toxicol. Appl. Pharmacol. 80: 137-147.
78. Juchau, M. R., Fantel, A. G., Harris, C. and Beyer, B. K. 1986. The potential role of redox cycling as a mechanism for chemical teratogenesis. Environ. Health Perspect. 70: 131-136.
79. Juchau, M. R., Lee, Q. P., and Fantel, A. G. 1992. Xenobiotics biotransformation/bioactivation in organogenesis-stage conceptal tissues: implications for embryotoxicity and teratogenesis. Drug Metab. Rev. 24: 195-238.
80. Jurima-Romet, M. and Shek, P. N. 1991. Lung uptake of liposome-entrapped glutathione after intratracheal administration. J. Pharm. Pharmacol. 43: 6-10.
81. Kanekal, S. and Kehrer, J. P. 1993. Metabolism of cyclophosphamide by lipoxygenases. Drug Metab. Dispos. 22: 74-78.
82. Kappus, H. 1986. Overview of enzyme systems involved in bio-reduction of drugs and in redox cycling. Biochem. Pharmacol. 35: 1-6.
83. 2 system. Drug Metab. Dispos. 19: 184-187.
84. Kim, P. M. and Wells, P. G. 1993. Salicylate hydroxylation as an in vivo probe for hydroxyl radical formation in CD-1 mice: relevance to phenytoin teratogenicity. Toxicologist 13: 253.
85. Kim, P. M. and Wells, P. G. 1996. Phenytoin hydroxyl radical formation: characterization by enhanced salicylate hydroxylation. Mol. Pharmacol. 49: 172-181.
86. Kim, P. K., Winn, L. M., Parman, T., and Wells, P. G. Submitted. UDP-glucuronosyltransferase-mediated protection against in vitro DNA oxidation, micronucleus formation and embryotoxicity initiated by phenytoin and its major metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH).
87. Kitada, M. and Kamataki, T. 1994. Cytochrome P450 in human fetal liver: significance and fetal-specific expression. Drug Metab. Rev. 26: 2305-2323.
88. Kitchin, K. T., Schmid, B. P., and Sanyal, M. K. 1981. Teratogenicity of cyclophosphamide in a coupled microsomal activating/embryo culture system. Biochem. Pharmacol. 30: 59-64.
89. Kromidas, L., Trombetta, L. D., and Jamall, I. S. 1990. The protective effects of glutathione against methyl mercury cytotoxicity. Toxicol. Lett. 51: 67-80.
90. Kubow, S. 1992. Inhibition of isotretinoin teratogenicity by acetylsalicylic acid pretreatment in mice. Teratology 45: 55-63.
91. Kubow, S. and Wells, P. G. 1986. In vitro evidence for prostaglandin synthetase-catalyzed bioactivation of phenytoin to a free radical intermediate. Pharmacologist 28: 195.
92. Kubow, S. and Wells, P. G. 1988. In vitro evidence for lipoxygenase-catalyzed bioactivation of phenytoin. Pharmacologist 30: A74.
93. Kubow, S. and Wells, P. G. 1989. In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthetase, horseradish peroxidase and thyroid peroxidase. Mol. Pharmacol 35: 504-511.
94. Laposa, R. R. and Wells, P. G. 1995. Preliminary evaluation of phenytoin teratogenicity in transgenic mice deficient in the p53 tumor suppressor gene. Toxicologist 15: 161.
95. Laposa, R. L., Chan, K. C., Wilewy, M. J., and Wells, P. G. 1996. Enhanced phenytoin embryopathy in p53-deficient mice: characterisation of embryonic p53 genotype and the p53, p21 and Bax DNA damage response proteins. Toxicologist 16: 997.
96. Larsson, A. and Hagenfeldt, L. 1983. Hereditary glutathione synthetase deficiency in man. In: Functions of Glutathione: Biochemical, Physiological, Toxicological, and Clinical Aspects. pp. 317-324. (Larsson, A., Orrenius, S., Holmgren, A., and Hannervik, B., Eds.) New York: Raven Press.
97. Lear, L., Nation, R. L., and Stupans, I. 1992. Effects of cyclophosphamide and adriamycin on rat hepatic microsomal glucuronidation and lipid peroxidation. Biochem. Pharmacol. 44: 747-753.
98. Lenz, W. 1961. Kindliche Missbildungen nach Medikament-Einnahme wahrend der Graviditat? Dtsch. Med. Wochenschr. 86: 2555-2556.
99. Lenz, W. 1962, Thalidomide and congenital anomalies. Lancet 1: 45.
100. Little, S. A. and Mirkes, P. E. 1987. DNA cross-linking and single-strand breaks induced by teratogenic concentrations of 4-hydroperoxycyclophosphamide and phosphoramide mustard in postimplantation rat embryos. Cancer Res. 47: 5421-5426.
101. Liu, L. and Wells, P. G. 1994a. In vitro and in vivo cytochromes P450- and peroxidase-catalysed formation of phenytoin-DNA adducts in murine maternal hepatic and embryonic tissues. In: Proc. 10th International Symposium on Microsomes and Drug Oxidations, p. 555, Toronto, Canada, July 1994.
102. Liu, L. and Wells, P. G. 1994b. In vivo phenytoininitiated oxidative damage to proteins and lipids in murine maternal hepatic and embryonic tissue organelles: potential molecular targets mediating chemical teratogenesis. Toxicol. Appl. Pharmacol. 125: 247-255.
103. Liu, L. and Wells, P. G. 1995a. Potential molecular targets mediating chemical teratogenesis: in vitro peroxidase-catalysed phenytoin metabolism and oxidative damage to proteins and lipids in murine maternal hepatic microsomes and embryonic 9000 g supernatant. Toxicol. Appl. Pharmacol. 134: 71-80.
104. Liu, L. and Wells, P. G. 1995b. DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2′-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues. Free Rad. Biol. Med. 19: 639-648.
105. Loch-Caruso, R. and Baxter, C. S. 1984. DNA damage and repair in embryonic mouse limbs exposed to teratogenic doses of methylnitrosourea. Mutat. Res. 131: 147-155.
106. Loiseau, P. and Duche, B. 1989. Potential antiepileptic drugs: stiripentol. In: Antiepileptic Drugs, 3rd ed., pp. 955-969. (Levy, R., Mattson, R., Meldrum, B., Penry, J. K., and Dreifuss, F. E., Eds.) New York: Raven Press.
107. Lu, L.-J. W., Anderson, L. M., Jones, A. B., Moskal, T. J., Salazar, J. J., Hokanson, J. A., and Rice, J. M. 1993. Persistence, gestation stage-dependent formation and interrelationship of benzo[a]pyrene-induced DNA adducts in mothers' placentae and fetuses of erythroceubs patas monkeys. Carcinogenesis 14: 1805-1813.
108. Lum, J. T. and Wells, P. G. 1986. Pharmacological studies on the potentiation of phenytoin teratogenicity by acetaminophen. Teratology 33: 53-72.
109. Manson, J. 1986. Teratogens. In: Toxicology, The Basic Science of Poisons, pp. 195-220. (Klaassen, C. D., Amdur, M. D., and Doull, J., Eds.) New York: Macmillan.
110. Marnett, L. J., Wlodawer, P., and Samuelsson, B. 1975. Co-oxygenation of organic substrates by prostaglandin synthetase of sheep vesicular gland. J. Biol. Chem. 250: 8510-8517.
111. Marnett, L. J., Reed, G. A., and Johnson, J. T. 1977. Prostaglandin synthase-dependent benzo[a]pyrene oxidation: products of the oxidation and inhibition of their formation by antioxidants. Biochem. Biophys. Res. Commun. 79: 569-576.
112. Marnett, L. J., Reed, G. A., and Dennison, D. J. 1978. Prostaglandin synthase dependent activation of 7,8-dihydro-7,8-dihydroxylbenzo[a] pyrene to mutagenic derivatives. Biochem. Biophys. Res. Commun. 82: 210-216.
113. Marnett, L. J. 1990. Prostaglandin synthase mediated metabolism of carcinogens and a potential role for peroxyl radicals as reactive intermediates. Environ. Health Perspect. 88: 5-12.
114. Martz, F., Failinger, C., and Blake, D. A. 1977. Phenytoin teratogenicity: correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational mouse. J. Pharmacol. Exp. Ther. 203: 231-239.
115. McBride, 1961. Thalidomide and congenital abnormalities. Lancet 2: 1358.
116. Mehta, A. B. 1994. Glucose-6-phosphate dehydrogenase deficiency. Postgrad. Med. J. 70: 871-877.
117. Meister, A. 1983. Metabolism and transport of glutathione and other gamma-glutamyl compounds. In: Functions of Glutathione: Biochemical, Physiological, Toxicological, and Clinical Aspects, pp. 1-93. (Larsson, A., Orrenius, S., Holmgren, A., and Mannervik, B., Eds.) New York: Raven Press.
118. Miranda, A. F., Wiley, M. J., and Wells, P. G. 1994. Evidence for embryonic peroxidase-catalysed bioactivation and glutathione-dependent cytoprotection in phenytoin teratogenicity: modulation by eicosatetraynoic acid and buthionine sulfoximine in murine embryo culture. Toxicol. Appl. Pharmacol. 124: 230-241.
119. Mirkes, P. E., Little, S. A., Beland, F. A., Huitfeldt, H. S., and Poirier, M. C. 1991. Quantitation and immunohistochemical localization of DNA adducts in rat embryos and associated yolk sac membranes exposed in vitro to N-acetoxy-2-acetylaminofluorene (N-Ac-AAF). Teratogen. Carcinogen. Mutagen. 11: 93-102.
120. Modrich, P. 1995. Mismatch repair, genetic stability and tumour avoidance. Philos. Trans. R. Soc. London Ser. B. 347: 89-95.
121. Nau, H. 1994. Retinoid teratogenesis: toxicokinetics and structure-specificity. Arch. Toxicol. (Suppl.) 16: 118-127.
122. Nebert, D. W. 1983. Genetic differences in drug metabolism: proposed relationship to human birth defects. In: Handbook of Experimental Pharmacology, Vol. 65, Teratogenesis and Reproductive Toxicology, pp. 49-62. (Johnson, E. M. and Kochhar, D. M., Eds.) New York: Springer-Verlag.
123. New, D. A. T. 1978. Whole embryo culture and the study of mammalian embryos during organogenesis. Biol. Rev. 53: 81-122.
124. Nicol, C. J., Harrison, M. L., Laposa, R. R., Gimelshtein, I. L., and Wells, P. G. 1995. A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. Nature Genet. 10: 181-187.
125. Nicol, C. J. and Wells, P. G. 1996. Glucose-6-phosphate dehydrogenase (G6PD): an embryoprotective role in endogenous oxidative stress and phenytoin teratogenesis. Toxicologist 16: 1008.
126. Nishikido, N., Furuyashiki, K., Naganuma, A., Suzuki, T., and Imura, N. 1987. Maternal selenium deficiency enhances the fetolethal toxicity of methyl mercury. Toxicol. Appl. Pharmacol. 88: 322-328.
127. Nonogaki, T., Noda, Y., Narimoto, K., Umaoka, Y., and Mori, T. 1992. Effects of superoxide dismutase on mouse in vitro fertilization and embryo culture system. J. Assist. Reprod. Genet. 9: 274-280.
128. Noda, Y., Matsumoto, H., and Mori, T. 1989. Superoxide dismutase overcomes 2-cell block in mouse embryos. Acta. Obstet. Gynaecol. Jpn. 41: 751-752.
129. Noda, Y., Matsumoto, H., Umaoka, Y., Tatsumi, K., Kishi, J., and Mori, T. 1991. Involvement of superoxide radicals in the mouse 2-cell block. Mol. Reprod. Dev. 28: 356-360.
130. Otto, S., Marcus, C., Pidgeon, C., and Jefcoate, C. 1991. A novel adrenocorticotrophin-inducible cytochrome P450 from rat adrenal microsomes catalyzes polycyclic aromatic hydrocarbon metabolism. Endocrinology 129: 970-982.
131. Otto, S., Bhattacharyya, K. K., and Jefcoate, C. R. 1992. Polycyclic aromatic hydrocarbon metabolism in rat adrenal, ovary and testis microsomes is catalyzed by the same novel cytochrome P450 (P450RAP). Endocrinology 131: 3067-3076.
132. Ornaghi, F., Ferrini, S., Pratt, M., and Giavini, E. 1993. The protective effects of N-acetyl-L-cysteine against methyl mercury embryotoxicity in mice. Fundam. Appl. Toxicol. 20: 437-445.
133. Ozolins, T. R. S., Oglesby, L. A., Wiley, M. J., and Wells, P. G. 1995a. In vitro murine embryopathy of cyclophosphamide in embryos co-cultured with maternal hepatocytes: development and application of a murine embryohepatocyte co-culture model. Toxicology 102: 259-274.
134. Ozolins, T. R. S., Wiley, M. J., and Wells, P. G. 1995b. Phenytoin covalent binding and embryopathy in murine embryos co-cultured with maternal hepatocytes from mouse, rat and rabbit. Biochem. Pharmacol. 50: 1831-1840.
135. Ozolins, T. R. S., Siksay, D. L. A., and Wells, P. G. 1996. Selenium-dependent modulation of glutathione peroxidase activities and phenytoin teratogenicity. J. Pharmacol. Exp. Ther. In press.
136. Panich, V. 1986. G6PD variants in southern Asian populations. In: Glucose-6-phosphate Dehydrogenase, pp. 195-241. (Yoshida, A. and Beutler, E., Eds.), New York: Academic Press.
137. Pantarotto, C., Arbix, M., Sezzano, P., and Abbruzzi, R. 1982. Studies on 5,5-diphenyl hydantoin irreversible binding to rat liver microsomal proteins. Biochem. Pharmacol. 31: 1501-1507.
138. Parman, T., Chen, G., Bray, T. M., and Wells, P. G. 1996. Bioactivation of phenytoin, thalidomide and related teratogens to a free radical intermediate using prostaglandin H synthase (PHS) or hepatic microsomes: characterization by electron spin resonance (ESR) spectrometry. Toxicologist 16: 1260.
139. Pillans, P. I., Ponzi, S. F., and Parker, M. I. 1989. Cyclophosphamide induced DNA strand breaks in mouse embryo cephalic tissue in vivo. Carcinogenesis 10: 83-85.
140. Platzek, T., Bochert, G., Meister, R., and Neubert, D. 1993. Embryotoxicity induced by alkylating agents. VII. Low dose prenatal-toxic risk estimation based on NOAEL risk factor approach, dose-response. Relationships and DNA adducts using methylnitrosourea as a model compound. Teratogen. Carcinogen. Mutagen. 13: 101-125.
141. Platzek, T., Bochert, G., and Rahm, T. 1994a. Embryotoxicity induced by alkylating agents. VIII. DNA adduct formation induced by ethylmethanesulfonate in mouse embryos. Teratogen. Carcinogen. Mutagen. 14: 65-73.
142. Platzek, T., Schwabe, R., Rahm, U., and Bochert, G. 1994b. DNA modification induced by 6-mercaptopurine riboside in murine embryos. Chem. Biol. Interact. 93: 59-71.
143. Platzek, T., Bochert, G., Pauli, B., Meister, R., and Neubert, D. 1988. Embryotoxicity induced by alkylating agents: 5 dose-response relationships of teratogenic effects of methylnitrosourea in mice. Arch. Toxicol. 62: 411-423.
144. Ponz de Leon, M. 1994. Cancer-prone hereditary diseases associated with abnormalities of DNA repair. Recent Res. Cancer 136: 322-331.
145. Pottenger, L. H., Christou, M., and Jefcoate, C. R. 1991. Purification and immunological characterization of a novel cytochrome P450 from C3H/10T1/2 Cells. Arch. Biochem. Biophys. 286: 488-497.
146. Potter, D. W. and Hinson, J. A. 1987. Mechanisms of acetaminophen oxidation to N-acetyl-p-benzoquinone imine by horseradish peroxidase and cytochrome P450. J. Biol. Chem. 262: 966-973.
147. Radman, M., Matic, I., Halliday, J. A., and Taddei, F. 1995. Editing DNA replication and recombination by mismatch repair: from bacterial genetics to mechanisms of predisposition to cancer in humans. Philos. Trans. R. Soc. London Ser. B. 347: 97-103.
148. Raucy, J. L. and Carpenter, S. J. 1993. The expression of xenobiotic-metabolizing cytochromes P450 in fetal tissues. J. Pharmacol. Toxicol. Methods 29: 121-128.
149. Roberts, C. J. and Lowe, C. R. 1975. Where have all the conceptions gone? Lancet 1: 498-499.
150. Rolfe, B. E. 1982. Detection of fetal wastage. Fertil. Steril. 37: 655-660.
151. Roy, D. and Snodgrass, W. R. 1990. Covalent binding of phenytoin and modulation of diphenylhydantoin metabolism by thiols in A/J mouse liver microsomes. J. Pharmacol. Exp. Ther. 252: 895-900.
152. Roy, S. K. and Kulkarni, A. P. 1991. Lipoxygenase: a new pathway for 2-aminofluorene bioactivation. Cancer Lett. 60: 33-39.
153. Saillenfait, A.-M., Payan, J.-P., Langonne, I., Beydon, D., Grandclaude, M.-C., Sabate, J.-P., and de Ceaurriz, J. 1993. Modulation of acrylonitrile-induced embryotoxicity in vitro by glutathione depletion. Arch. Toxicol. 67: 164-172.
154. Samokyszyn, V. M., Sloane, B. F., Honn, K. V., and Marnett, L. J. 1984. Cooxidation of 13-cis-retinoic acid by prostaglandin H synthase. Biochem. Biophys. Res. Commun. 124: 430-436.
155. Sancar, A. 1994. Mechanisms of DNA excision repair. Science 266: 1954-1956.
156. Sanyal, M. K., Kitchin, K. T., and Dixon, R. L. 1979. Anomalous development of rat embryos cultured in vitro with cyclophosphamide and microsomes. Pharmacologist 21: 231.
157. Sanyal, S. and Wells, P. G. 1993. Reduction in phenytoin teratogenicity by pretreatment with the antioxidant d-a-tocopherol acetate (vitamin E) in CD-1 mice. Toxicologist 13: 252.
158. Sato, J. 1988. Glutathione S-transferases and hepatocarcinogenesis. Jpn. J. Cancer Res. 79: 556-572.
159. Savas, U., Bhattacharyya, K. K., Christou, M., Alexander, D. L., and Jefcoate, C. R. 1994. Mouse cytochrome P-450EF, representative of a new 1B subfamily of cytochrome P-450s. J. Biol. Chem. 269: 14905-14911.
160. Shanks, M. J., Wiley, M. J., Kubow, S., and Wells, P. G. 1989. Phenytoin teratogenicity: role of enzymatic bioactivation in a murine embryo culture model. Teratology 40: 311-320.
161. Shum, S., Jensen, N. M., and Nebert. D. W. 1979. The murine Ah locus: in utero toxicity and teratogenesis associated with genetic differences in benzo[a]pyrene metabolism. Teratology 20: 365-376.
162. Slott, V. L. and Hales, B. F. 1987. Enhancement of the embryotoxicity of acrolein, but not phosphoramide mustard by glutathione depletion in rat embryos in vitro. Biochem. Pharmacol. 36: 2019-2025.
163. Smith, R. G., Daves, G. D., Jr., Lynn, R. K., and Gerber, N. 1977. Hydantoin ring glucuronidation: characterization of a new metabolite of 5,5-diphenyl hydantoin in man and the rat. Biomed. Mass Spectrom. 4: 275-279.
164. Spielberg, S. P. 1985. Acetaminophen toxicity in lymphocytes heterozygous for glutathione synthetase deficiency. Can. J. Physiol. Pharmacol. 63: 468-471.
165. Stark, K. L., Harris, C., and Juchau. M. R. 1987. Embryotoxicity elicited by inhibition of gamma-glutamyltransferase by acivicin and transferase antibodies in cultured rat embryos. Toxicol. Appl. Pharmacol. 89: 88-97.
166. Strickler, S. M., Dansky, L. V., Miller, M. A., Seni, M. H., Andermann, E., and Spielberg, S. P. 1985. Genetic predisposition to phenytoin induced birth defects. Lancet 2: 746-749.
167. Suntres, Z. E. and Shek, P. N. 1994. Incorporation of a-tocopherol in liposomes promotes the retention of liposome-encapsulated glutathione in the rat lung. J. Pharm. Pharmacol. 46: 23-28.
168. Terlouw, G. D. C., Namkung, M. J., Juchau, M. R., and Bechter, R. F. 1993. In vitro embryotoxicity of N-methyl-N-(7-propoxynaphthalene-2-ethyl)-hydroxy lamine (QAB): evidence for N-dehydroxylated metabolite as a proximate dysmorphogen. Teratology 48: 431-439.
169. Tonoki, H. 1994. Establishment of Chinese hamster ovary cell lines with reduced expression of glutathione reductase after antisense-oriented gene transfection and assessment of the sensitivity to oxidant injury. Hokkaido J. Med. Sci. 69: 1261-1274.
170. Uetrecht, J. and Zahid, N. 1988. N-chlorination of phenytoin by myeloperoxidase to a reactive metabolite. Chem. Res. Toxicol. 1: 148-151.
171. Veronese, M. E., Mackenzie, P. I., Doecke, C. J., McManus, M. E., Miners, J. O., and Birkett, D. J. 1991. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem. Biophys. Res. Commun. 3: 1112-1118.
172. Vienneau, D. S., DeBoni, U., and Wells, P. G. 1995. Potential genoprotective role for UDP-glucuronosyltransferases (UGTs) in chemical carcinogenesis: initiation of micronuclei by benzo[a]pyrene and benzo[e]pyrene in UGT-deficient cultured rat skin fibroblasts. Cancer Res. 55: 1045-1051.
173. Wang, M. Y., and Lu, L. J. W. 1990. Differential effect of gestation stage on benzo[a]pyrene-induced micronucleus formation and/or covalent DNA modifications in mice. Cancer Res. 50: 2146-2151.
174. Wells, P. G. and Gesicki, I. B. 1984. Modulation of phenytoin teratogenicity by exogenous and endogenous inhibitors of oxidative drug metabolism. In: Proceedings of the 9th International Congress of Pharmacology, 1772P. London, U.K.
175. Wells, P. G. 1989. Chemical teratogenesis. In: Principles of Medical Pharmacology, 5th ed., pp. 644-657. (Kalant, H. and Roschlau, W. H. E. Eds.) Toronto: B. C. Decker.
176. Wells, P. G. and Vo, H. P. N. 1989. Effect of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) on phenytoin embryopathy. Toxicol. Appl. Pharmacol. 97: 398-405.
177. Wells, P. G. and Harbison, R. D. 1980. Significance of the phenytoin reactive arene oxide intermediate, its oxepin tautomer, and clinical factors modifying their role in phenytoin-induced teratology. In: Phenytoin-Induced Teratology and Gingival Pathology, pp. 83-108. (Hassell, T. M., Johnston, M. C., and Dudley, K. H., Eds.) New York: Raven Press.
178. Wells, P. G., Obilo, F. C., and de Morais, S. M. F. 1989a. Benzo[a]pyrene embryopathy in rats genetically deficient in bilirubin UDP-glucuronyl transferase. FASEB J. 3: A1025.
179. Wells, P. G., Nagai, M. K., and Spano Greco, G. 1989b. Inhibition of trimethadione and dimethadione teratogenicity by the cyclooxygenase inhibitor acetylsalicylic acid: a unifying hypothesis for the teratologic effects of hydantoin anticonvulsants and structurally related compounds. Toxicol. Appl. Pharmacol. 97: 406-414.
180. Wells, P. G., Zubovits, J. T., Wong, S. T., Molinari, L. M., and Ali, S. 1989c. Modulation of phenytoin teratogenicity and embryonic covalent binding by acetylsalicylic acid, caffeic acid and alpha-phenyl-N-t-butylnitrone: implications for bioactivation by prostaglandin synthetase. Toxicol. Appl. Pharmacol. 97: 192-202.
181. Wells, P. G., Davidovich, O., and Mark, T. M. 1991. Inhibition of murine phenytoin teratogenicity by the iron chelator deferoxamine. Toxicologist 11: 293.
182. Wells, P. G. and Srivastava, S. 1992. Enhancement of phenytoin fetal and maternal toxicity by low-level exposure to methylmercury. Toxicologist 12: 309.
183. Wells, P. G. and Williams, L. M. 1994. Effect of phenytoin on embryonic soluble thiols and disulfides in murine embryo culture. Toxicologist 14: 164.
184. Wells, P. G., Leader, J. S., and Winn, L. M. 1995. Phenytoin-initiated protein oxidation in murine embryo culture: a potential molecular mechanism mediating phenytoin teratogenicity. Toxicologist 15: 276.
185. Wells, P. G., and Kim, P. M. 1996. UDP-glucuronosyltransferase (UGT)-mediated genoprotection in phenytoin- and 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH)-initiated DNA oxidation and micronucleus formation. Toxicologist 16: 1201.
186. Wells, P. G., Kim, P. M., Nicol, C. J., Parman, T., and Winn, L. M. 1996. Reactive intermediates, In: Handbook of Experimental Pharmacology: Drug Toxicity in Embryonic Development, chap. 17. (Kavlock, R. J. and Daston, G. P., Eds.) Heidelberg: Springer-Verlag, in press.
187. Williams, G. M. and Weisburger, J. H. 1991. Chemical carcinogenesis. In: Casarett and Doull's Toxicology: The Basic Science of Poisons, 4th ed. pp. 127-200. (Amdur, M. O., Doull, J., and Klaassen, C. D., Eds.) New York: McGraw-Hill.
188. Wilson, J. G. 1973. Present status of drugs as teratogens in man. Teratology 7: 3-16.
189. Winn, L. M. and Wells, P. G. 1994. Benzo[a] pyrene-initiated DNA and protein oxidation in murine embryo culture: a potential molecular mechanism mediating benzo[a]pyrene teratogenicity. In: Proc. 27th Annual Symposium of the Society of Toxicology of Canada, p. 77.
190. Winn, L. M. and Wells, P. G. 1995a. Free radical-mediated mechanisms of anticonvulsant teratogenicity. Eur. J. Neurol. 2 (Suppl. 4): 5-29.
191. Winn, L. M. and Wells, P. G. 1995b. Phenytoininitiated DNA oxidation in murine embryo culture, and embryoprotection by the antioxidative enzymes superoxide dismutase and catalase: evidence for reactive oxygen species mediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity. Mol. Pharmacol. 48: 112-120.
192. Winn, L. M. and Wells, P. G. 1996. Enhancement of embryonic activity of superoxide dismutase (SOD) and inhibition of benzo[a]pyrene embryopathy in embryo culture by exogenous addition of SOD. Toxicologist 16: 1249.
193. Winn, L. M. and Wells, P. G. 1996. Evidence for embryonic prostaglandin H synthase-catalyzed bioactivation and reactive oxygen species-mediated oxidation of macromolecules in phenytoin and benzo[a]pyrene teratogenesis. Free Rad. Biol. Med. In press.
194. Wong, M. and Wells, P. G. 1988. Effects of N-acetylcysteine on fetal development and phenytoin teratogenicity in mice. Teratogen. Carcinogen. Mutagen. 8: 65-79.
195. Wong, M. and Wells, P. G. 1989. Modulation of embryonic glutathione reductase and phenytoin teratogenicity by 1,3-bis(2-chloroethyl)-1-nitrosourea. J. Pharmacol. Exp. Ther. 250: 336-342.
196. Wong, M., Helston, L. M. J., and Wells, P. G. 1989. Enhancement of murine phenytoin teratogenicity by the gamma-glutamylcysteine synthetase inhibitor buthionine sulfoximine and the glutathione depletor diethylmaleate. Teratology 40: 127-141.
197. Wrighton, S. A. and Stevens, J. C. 1992. The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22: 1-21.
198. Wubah, J. A., Ibrahim, M. M., Gao, X., Nguyen, D., Pisano, M. M., and Knudsen, T. B. 1996. Teratogen-induced eye defects mediated by p53-dependent apoptosis. Curr. Biol. 6: 60-69.
199. Yang, H.-Y. L., Lee, Q. P., Rettie, A. E., and Juchau, M. R. 1994. Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol. Pharmacol. 46: 922-928.
200. Yoneyama, M., Ogata, A., and Hiraga, K. 1985. Irreversible in vivo binding of thiabendazole to macromolecules in pregnant mice and its relation to teratogenicity. Fd. Chem. Toxic. 23: 733-736.
201. Yoneyama, M. and Ichikawa, H. 1986. Irreversible in vivo and in vitro binding of thiabendazole to tissue protein of pregnant mice. Fd. Chem. Toxic. 24: 1283-1286.
202. Yu, W. K. and Wells, P. G. 1995. Evidence for lipoxygenase-catalyzed bioactivation of phenytoin to a teratogenic reactive intermediate: in vitro studies using linoleic acid-dependent soybean lipoxygenase, and in vivo studies using pregnant CD-1 mice. Toxicol. Appl. Pharmacol. 131: 1-12.
203. Ziegler, M. H., Grafton, T. F., and Hansen, D. K. 1993. The effect of tolbutamide on rat embryonic development in vitro. Teratology 48: 45-51.
204. Zimmerman, E. F., Potturi, R. B., Resnick, E., and Fisher, J. E. 1994. Role of oxygen free radicals in cocaine-induced vascular disruption in mice. Teratology 49: 192-201.